Abstract
The antineoplastic activity that taxol has demonstrated in advanced ovarian cancer and other neoplasms in which the platinum analogues are among the most active agents has been the impetus for the development of taxol/platinum combination regimens. Since both classes of agents are known to induce cell-cycle-dependent effects and to delay cell-cycle traverse in specific phases of the cycle, an evaluation of drug sequence dependence was incorporated into initial clinical studies of the drug combination. To complement clinical studies, sequence-dependent interactions were assessed in vitro using L1210 leukemia. Cytotoxicity resulting from the combination of taxol and cisplatin was significantly increased over that achieved with cisplatin alone only when cisplatin was administered after taxol. This sequence was significantly superior to both the reverse sequence and to simultaneous drug treatment. Results achieved with sequence iterations of vincristine and cisplatin were nearly identical. In addition, alkaline-elution studies, using the optimal sequence of cisplatin and either taxol or vincristine, demonstrated that these antimicrotubule agents do not increase the formation of cisplatin-induced DNA interstrand and DNA-protein crosslinking over that produced by cisplatin alone. Although the mechanisms for the sequence-dependent cytotoxic interactions between cisplatin and the antimicrotubule agents have not been determined, it is likely that antagonistic interactions occur with the suboptimal sequences, probably because of cell-cycle-dependent phenomena.
Similar content being viewed by others
References
Benz C, Tillis T, Tattleman E, Cadman E (1982) Optimal scheduling of methotrexate and 5-fluorouracil in human breast cancer. Cancer Res 42:2081–2086
Bergerat J-P, Barlogie, B, Drewinko B (1979) Effects ofcis-dichlorodiammineplatinum (II) on human colon carcinoma cells in vitro. Cancer Res 39:1334–1338
Bertino JR, Sawicki WL, Linquist CA, Gupta VS (1977) Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil, Cancer Res 37:327–328
Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F (1991) Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51:4845–4852
Bissett D, Graham MA, Setanians A, Chadwick GA, Wilson P, Koier I, Henrar R, Schwartsmann G, Cassidy J, Kaye SB, Kerr DJ (1992) Phase I and pharmacokinetic study of rhizoxin. Cancer Res 52:2894–2898
Chang A, Kim K, Glick J, Anderson T, Karp D, Johnson D (1992) Phase II study of taxol in patients with stage IV nonsmall cell lung cancer (NSCLC): the Eastern Cooperative Oncology Group (ECOG) results. Proc Am Soc Clin Oncol 11:293
Chou J, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs and enzyme inhibitors. Adv Enzyme Regul 22:27–55
Chu M-Y, Fisher GA (1968) The incorporation of3H-cytosine arabinoside and its effect on murine leukemic cells (L5178Y). Biochem Pharmacol 17:753–767
Crossin KL, Carney DH (1981) Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and epidermal growth factor. Cell 27:341–350
Einzig AI, Wiernik P, Sasloff J, Runowicz CD, Goldberg GL (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748–1753
Forastiere A, Neuberg D, Taylor SG IV. Phase II evaluation of taxol in advanced head and neck cancer (1993) JNCI (in press)
Fraval HNA, Roberts JJ (1978) G1 phase Chinese hamster V79-379A cells are inherently more sensitive to platinum bound to their DNA than mid S-phase or asynchonously treated cells. Biochem Pharmacol 28:1575–1580
Fraval HNA, Roberts JJ (1981) Excision repair ofcis-diamminedichloroplatinum(II)-induced damage to DNA of Chinese hamster cells. Cancer Res 39:1793–1797
Hilton J (1984) Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and-resistant L1210 cells. Biochem Pharmacol 33:1867–1872
Himelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA (1981) Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 29:658–664
Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, and active drug in metastatic breast cancer. JNCI 83:1797–1805
Jackson DV, Bender RA (1979) Cytotoxic thresholds of vincristine in a murine a human leukemia cell line in vitro. Cancer Res 39:4346–4349
Kohn KW, Erickson LC, Ewig RAG, Friedman CA (1976) Fractionation of DNA from mammalian cells by alkaline elution. Biochemistry 15:4629–4637
Kopf-Maier P, Wagner W, Liss E (1983) Induction of cell arrest at G1/S and in G2 after treatment of Ehrlich ascites tumor cells with metallocene dichlorides and cis-platinum in vitro. J Cancer Res Clin Oncol 106:44–52
Krishan A, Frei E (1975) Morphological basis for the cytolytic effect of vinblastine and vincristine on cultured leukemic lymphoblasts. Cancer Res 35:497–501
Lee K, Tanaka M, Kanamaru H, Hashimura T, Yamamoto I, Konishi J (1989) In vitro antagonism between cisplatin and vinca alkaloids. Br J Cancer 59:36–41
Macdoc-Jones H, Mauro F (1968) Interphase action of vinblastine and vincristine: differences in their lethal action through the mitotic cycle of cultured mammalian cells. J Cell Physiol 72:185–196
McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273–279
Murphy WK, Winn RJ, Fossella FV, Shin DM, Hynes HE, Gross HM, Davila E, Leimert JT, Dhingra HM, Raber MN, Krakoff IH, Hong WK (1992) A phase II study of taxol (NSC 125973) in patients (pts) with non-small cell lung cancer (NSCLC). Proc. Am Soc Clin Oncol 11:294
Natale R, Waterhouse D, Grove W, Whitfield LR, Bodfuehrer J, Kowal C (1992) Phase I clinical and pharmacokinetic trial of CI-980, a novel mitotic inhibitor. Proc Am Soc Oncol 11:118
Peyrot V, Briand C, Crevat A (1983) Action of hydrolyzed cisplatin and some analogs on microtubule protein polymerization in vitro. Cancer Treat Rep 67:641–646
Potier P (1989) The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol [Suppl 4] 16:2–4
Ringel I, Horwitz SB (1991) Studies with RP56976 (taxotere): a semisynthetic analogue of taxol. JNCI 83:288–291
Roberts JJ, Fravel HNA (1978) The interaction of antitumor platinum compounds with cellular DNA in cultured and animal tissues: relationship to DNA cellular repair processes. Biochimie 60:869–877
Roberts JR, Rowinsky EK, Donehower RC, Allison DC (1989) Demonstration of the cell cycle positions for taxol-induced “asters” and “bundles” by measurement of fluorescence, Feulgen-DNA content, and autoradiographic labeling of the same cells. J Histochem Cytochem 37:1659–1665
Roberts JR, Allison DC, Dooley WC, Donehower RC, Rowinsky EK (1990) Effects of taxol on cell cycle traverse: taxol-induced polyploidization as a marker for drug resistance. Cancer Res 50:710–716
Rosner F, Hirshaut Y, Grunwald HW, Dietrich M (1975) In vitro combination chemotherapy demonstrating potentiation of vincristine cytotoxicity by prednisone. Cancer Res 35:700–705
Rowinsky EK, Donehower RC, Jones RJ, Tucker RW (1988) Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48:4093–4100
Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antineoplastic agent. JNCI 82:1247–1259
Rowinsky EK, Gilbert M, McGuire WP, Ettinger DS, Forastiere A, Grochow LB, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692–1703
Sarosy G, Kohn E, Stone DA, Rothenberg M, Jakob J, Adamo DO, Ogenbene FP, Cunnion RE, Reed E (1992) Phase I Study of taxol and granulocyte Colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10:1165–1170
Schiff PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561–1565
Seidman A, Reichman B, Crown J, Begg C, Heelan R, Hakes T, Surbone A, Gilewski T, Lebwohl D, Currie V, Hudis C, Klecker R, Collins J, Toomasi F, Berkery R, Quinlivan S, Kelsen D, Norton L (1992) Activity of taxol with recombinant granulocyte colony-stimulating factor as first chemotherapy of patients with metastatic breast cancer. Proc Am Soc Clin Oncol 11:59
Sorenson CM, Eastman A (1988) Mechanism ofcis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 48:4484–4488
Sorenson CM, Barry MA, Eastman A (1990) Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin. Eur J Cancer 9:613–620
Thigpen T, Blessing J, Ball H, Hummel S, Barret R (1990) Phase II trial of taxol as second-line therapy for ovarian carcinoma: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 9:156
Vermorken JB, van der Vijgh WJF, Klein I, Gall HE, van Groeninger CJ, Hart GAM, Pinedo HM (1986) Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clin Pharmacol Ther 39:136–144
Yalowich JC (1987) Effect of microtubule inhibitors on etoposide accumulation and DNA damage in human K562 cells in vitro. Cancer Res 47:1010–1015
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rowinsky, E.K., Citardi, M.J., Noe, D.A. et al. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 119, 727–733 (1993). https://doi.org/10.1007/BF01195344
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01195344